» Articles » PMID: 10854165

Fine Characterization of a V3-region Neutralizing Epitope in Human Immunodeficiency Virus Type 2

Overview
Journal Virus Res
Specialty Microbiology
Date 2000 Jun 15
PMID 10854165
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously identified two distinct antigenic sites in the third variable region (V3) of human immunodeficiency virus type 2 (HIV-2) corresponding to the principal neutralizing determinant (PND) of HIV-1, the conserved Phe-His-Ser-Gln and Trp-Cys-Arg motifs (positions 315-318 and 329-331), which possibly interact to form a discontinuous antigenic site. The aim of this study was to further identify and characterize the immunogenic sites in the V3-loop of HIV-2 that are important in the binding of neutralizing antibodies and to study in detail the importance of different configurations of peptides corresponding to this region. Peptides representing modifications of the V3-region of HIV-2(SBL6669-ISY) were used for immunization of guinea pigs. With one exception, both the Phe-His-Ser-Gln and the Trp-Cys-Arg motifs were required in the peptide sequences to obtain neutralizing hyperimmune guinea pig sera, and the highest titers were obtained after immunization with 20-27 amino acids (aa) long peptides. Neither substitutions nor deletions of residues between the two motifs, nor the addition of peptide sequences representing a T-helper epitope improved the induction of neutralizing antibodies. Computer simulation modeling revealed that the Phe-315, His-316, Trp-329 and Cys-330 are likely to participate in the formation of a discontinuous epitope. Taken together, these data support the hypothesis that the well conserved motifs FHSQ (positions 315-318) and WCR (positions 329-331) of the HIV-2(SBL6669) V3 region are important targets for neutralizing antibodies, and this may have implications for the design of a future HIV-2 vaccine.

Citing Articles

HIV-2 and its role in conglutinated approach towards Acquired Immunodeficiency Syndrome (AIDS) Vaccine Development.

Diwan B, Saxena R, Tiwari A Springerplus. 2013; 2(1):7.

PMID: 23483108 PMC: 3586397. DOI: 10.1186/2193-1801-2-7.


Crystal structure of the HIV-2 neutralizing Fab fragment 7C8 with high specificity to the V3 region of gp125.

Uchtenhagen H, Friemann R, Raszewski G, Spetz A, Nilsson L, Achour A PLoS One. 2011; 6(4):e18767.

PMID: 21541316 PMC: 3082531. DOI: 10.1371/journal.pone.0018767.


Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.

Barroso H, Borrego P, Bartolo I, Maria Marcelino J, Familia C, Quintas A PLoS One. 2011; 6(1):e14548.

PMID: 21283793 PMC: 3024314. DOI: 10.1371/journal.pone.0014548.


Production, purification, crystallization and preliminary X-ray diffraction analysis of the HIV-2-neutralizing V3 loop-specific Fab fragment 7C8.

Uchtenhagen H, Sourial S, Friemann R, Ehnlund M, Spetz A, Harris R Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009; 65(Pt 7):705-8.

PMID: 19574645 PMC: 2705640. DOI: 10.1107/S1744309109020685.


Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.

Lizeng Q, Nilsson C, Sourial S, Andersson S, Larsen O, Aaby P J Virol. 2004; 78(13):7016-22.

PMID: 15194778 PMC: 421651. DOI: 10.1128/JVI.78.13.7016-7022.2004.